Pfizer Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (362)

Latest Posts

About This Stock More About This Stock
Merck KGaA And Pfizer Get FDA Approval Of Checkpoint Inhibitor "Avelumab" For Rare Merkel Cell Skin Cancer Therapy
Article By: Lorimer Wilson
Friday, March 24, 2017 10:17 AM EDT
Biopharma partners Merck KGaA and Pfizer came away with their first FDA approval of the checkpoint inhibitor avelumab, making it the fourth drug in this category to make it to the market.
In this article: MRK, PFE Also: AZN, BMY
Read
Who Are The Next Acquisition Targets In Dermatology?
Article By: Ari Zoldan
Wednesday, March 22, 2017 8:25 AM EDT
Specialty pharmaceuticals is a highly dynamic sector with robust stock valuations and an active mergers & acquisition market. One of the most attractive areas for investment is dermatology.
In this article: IMNP, AZN, PFE, SNY, ANAC, RGEN, DERM, FOMX, LBTSF
Read
Pfizer Mega Blockbuster Prevnar 13 Being Challenged By Upstart SutroVax
Article By: Lorimer Wilson
Tuesday, March 21, 2017 2:41 PM EDT
SutroVax has reeled in a whopping $64 million to get them well into human studies for a new vaccine that will challenge the Pfizer mega block buster Prevnar 13 for the heavyweight title in its field.
In this article: PFE
Read
Trump, Biogen And Amgen Hammer Healthcare ETFs
Article By: Sweta Killa
Monday, March 20, 2017 2:05 PM EDT
The initial sell-off came after Trump’s budget blueprint, which signaled higher regulatory costs for the sector and a cut in federal funding for medical research.
In this article: BIIB, AMG, PFE, CELG, ABT, TMO Also: ESPR, MDCO, BBH, IBB, BBP, XLV, VHT, IYH
Read
Competition Increases Between Novartis, Lilly & Pfizer For Approval Of New Breast Cancer Drug
Article By: Lorimer Wilson
Monday, March 20, 2017 12:38 PM EDT
Just one week after Novartis scored a key approval for its CDK 4/6 cancer drug, Eli Lilly & Co. has announced that its long-awaited Phase III readout for its rival drug "abemaciclib" looks good albeit remaining far behind Pfizer in the CDK 4/6 game.
In this article: LLY, NVS, PFE
Read

PARTNER HEADLINES

Latest Tweets for $PFE

No tweets yet!